Loading...

JAGX JAGUAR HEALTH INC Expansion Plans 8-K Filing

JGR

JGX

JAGUAR HEALTH INC

(JAGX)

2025 8-K

Show Summary

Summary

Equity Offerings

Debt Restructuring

Equity Offerings

Equity Offerings

Investor Meetings

Equity Offerings

Product Expansion

Investor Meetings

Debt Restructuring

Investor Meetings

Investor Presentation

Private Placement

Earnings Announcement

Securities Agreement

Stock Split Announcement

Stockholder Meeting

Dividend Declaration

ATM Agreement Amendment

Q3 Earnings Report

Q2 Earnings Report

FDA Trial Results

Amendment to Offering Agree...

Equity Issuance

Nasdaq Listing Compliance

Annual Meeting Results

Equity Issuance

Amendment to At the Market ...

Special Meeting Results

Securities Purchase and Exc...

Equity Disinvestment

Debt Extinguishment and Exc...

Lease Agreement Amendments

Amendments and Exchange Agr...

Earnings Reports

Management Changes

Amendment to Inducement Awa...

Earnings Reports

Private Placement

Earnings Reports

Nasdaq Listing Compliance

Termination of License Agre...

Reverse Stock Split

External Links:

On April 30, 2025, Jaguar Health, Inc. announced positive proof-of-concept results for crofelemer, showing a 27% reduction in total parenteral nutrition and improved stool frequency in patients with intestinal failure.

AI Assistant

JAGUAR HEALTH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.